Citation only
via Europe PMC
Mitochondrial pharmacology of cardiovascular and antidiabetic drugs: Mechanistic basis of cardioprotection and cardiotoxicity in the diseased heart.
Biochimica et biophysica acta. Molecular basis of disease · 2026
Mitochondrial dysfunction
Disabled macroautophagy
Metformin
Partial reprogramming (OSK)
Human
Review
Abstract
Mitochondrial function is a central determinant of cardiomyocyte survival, yet mitochondrial pharmacology remains under-integrated into cardiovascular and antidiabetic drug classification, safety assessment, and therapeutic decision-making. Many cardiometabolic drugs exert direct or indirect effects on mitochondrial bioenergetics, redox balance, calcium handling, quality control, and genome stability effects that can confer protection in some contexts while precipitating toxicity in others. In diseased myocardium, where mitochondrial reserve is constrained by ischemia, metabolic stress, ageing, or heart failure, these drug-mitochondria interactions frequently dictate clinical benefit or harm beyond the nominal drug class. This review synthesises the mitochondrial actions of widely used cardiovascular and antidiabetic therapies, including statins, renin-angiotensin-aldosterone system inhibitors, β-blockers, metformin, sodium-glucose cotransporter-2 inhibitors, and incretin-based agents, across acute and chronic exposure windows. We integrate key mechanistic domains encompassing electron transport chain modulation, redox and cofactor reprogramming, calcium permeability transition coupling, mitochondrial dynamics, mitophagy, and stress signalling, and relate these signatures to clinically relevant cardiometabolic disease contexts. We propose a unifying framework in which mitochondrial reserve capacity and quality control competence function as the central decision node determining whether pharmacologic mitochondrial engagement is adaptive or injurious. Finally, we outline principles for mitochondria-conscious prescribing, risk stratification, and drug development, and propose that systematic incorporation of mitochondrial endpoints into clinical trials and safety pipelines is essential for advancing precision cardiometabolic therapy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1016/j.bbadis.2026.168505
- Canonical
- link ↗
- Fetched
- 2026-10-25 MST
Cite this
APA
GA., K. (2026). Mitochondrial pharmacology of cardiovascular and antidiabetic drugs: Mechanistic basis of cardioprotection and cardiotoxicity in the diseased heart. <em>Biochimica et biophysica acta. Molecular basis of disease</em>. https://doi.org/10.1016/j.bbadis.2026.168505
Vancouver
GA. K. Mitochondrial pharmacology of cardiovascular and antidiabetic drugs: Mechanistic basis of cardioprotection and cardiotoxicity in the diseased heart. Biochimica et biophysica acta. Molecular basis of disease. 2026. doi:10.1016/j.bbadis.2026.168505.
BibTeX
@article{kurian2026Mitoch,
title = {Mitochondrial pharmacology of cardiovascular and antidiabetic drugs: Mechanistic basis of cardioprotection and cardiotoxicity in the diseased heart.},
author = {Kurian GA.},
journal = {Biochimica et biophysica acta. Molecular basis of disease},
year = {2026},
doi = {10.1016/j.bbadis.2026.168505},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging cell 2026
Open access · OA
Magnesium as a Bioenergetic Checkpoint Linking Mitochondrial Function, Metabolic Disease, and Aging.
Gut microbes 2026
Open access · OA
Mechanistic pathways linking gut microbial metabolites, microbial structural products, and host-microbe co-metabolites to mitochondrial function.
Molecular cell 2026
Citation only
Uncovering the initial response: Intra-mitochondrial surveillance activates the UPR<sup>mt</sup>.
Hearts 2020
Open access · CC-BY
Mechanisms Underlying Development of Taurine-Deficient Cardiomyopathy
Cell Death and Disease 2022
Open access · CC-BY
Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease
International Neurourology Journal 2019
Open access · CC-BY